FDA finds deficiencies in Mylan's generic Advair

Thomson Reuters

(Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

Mylan said http://newsroom.mylan.com/press-releases?item=123580 it expects to receive a formal complete response letter from the U.S. Food And Drug Administration on June 27 and would determine what impact, if any, it would have on its full-year forecast.

The company's shares fell 4 percent to $40.00 after the bell.

(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

See Also:

• Russian women should avoid sex with foreign men during World Cup: lawmaker

• Oil majors ask U.S. judge to toss New York City climate lawsuit

• Haiti withdraws Oxfam Great Britain's right to operate after misconduct scandal